Show simple item record

dc.contributor.authorPATERSON, JENNIFER
dc.date.accessioned2017-02-10T19:19:07Z
dc.date.available2017-02-10T19:19:07Z
dc.date.issued2006
dc.identifier.urihttp://hdl.handle.net/10222/72688
dc.description2005 NSIS Scientific Writing Awarden_US
dc.description.abstractIn the difficult world of drug discovery, two main courses of action are open: one is to screen extensive libraries of chemical compounds against hundreds of disease models; another is to acquire a detailed understanding of the molecules involved in a particular disease, and then rationally design compounds that can interact with or block those molecules. The first approach is favoured by large pharmaceutical companies, while the second is favoured by academics. This article illustrates the pursuit of this second approach by a Dalhousie University neurologist and chemist. Through interviews with this scientist and several of his colleagues, the article reveals the science of rational drug design, as well as some of the challenges and compromises involved in bringing discoveries to comm.ercial stages.en_US
dc.language.isoen_USen_US
dc.publisherNova Scotian Institute of Scienceen_US
dc.relation.ispartofProceedings of the Nova Scotian Institute of Scienceen_US
dc.titleRATIONAL DRUG DESIGN: A WINDOW INTO THE AMBITIOUS QUEST OF A NEUROLOGIST AND CHEMISTen_US
dc.typeArticleen_US
dc.identifier.volume43
dc.identifier.issue2
dc.identifier.startpage235
 Find Full text

Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record